Final analysis revealed SAEs in 36.1 % of adults receiving BIIL 284 BS vs. 21.2 % receiving placebo ( p = 0.007 ) , and in 29.6 % of children receiving BIIL 284 BS vs. 22.9 % receiving placebo ( p = 0.348 ) .